Yes, the data is obviously very good & woukd seem to align closely with the successful treatment of gut SRaGVHD.
Also very interesting question about the number of non-responders in SRaGVHD. I think SI said there should not be non-responders. Timing of treatment is the key. Very exciting to think of physicians being able to increase Ryoncil’s success in treating this disease.
Great presentation. SI spoke very confidently, especially about Ryoncilbeing second line treatment.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)